Galectin Therapeutics (GALT)

• Market cap: $174M
• 1 day: 0.76%
• 5 days: 12.82%
• 1 month: 20.55%
• 3 months: -16.98%
• 6 months: -57.42%
• Year to date: -34.81%
• 1 year: 77.18%
• 5 years: -24.36%
• 10 years: 92.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Employees: 9